New Frontiers in Intravesical Therapies and Drug Delivery

European Urology

Volumn 50, Issue 6, 2006, Pages 1183-1193

  Giannantoni, Antonella ^a   Di Stasi, Savino M ^b   Chancellor, Michael B ^c   Costantini, Elisabetta ^a   Porena, Massimo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Electric current; Intravesical drug administration; Permeability; Sustained delivery

Indexed keywords

ADRENALIN; AMINOLEVULINIC ACID; AMPHOTERICIN; AMPHOTERICIN B; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BCG VACCINE; BETHANECHOL; BOTULINUM TOXIN A; CAPSAICIN; CHITOSAN; DEFIBROTIDE; DEXAMETHASONE; DIMETHYL SULFOXIDE; GRAMICIDIN; LIDOCAINE; LIPOSOME; MELATONIN; METHYLENE BLUE; MITOMYCIN C; NYSTATIN; OXYBUTYNIN; PACLITAXEL; PIRARUBICIN; POLYMYXIN B; PROTAMINE SULFATE; RESINIFERATOXIN; UNINDEXED DRUG;

BLADDER CANCER; BLADDER DISCOMFORT; BLADDER DYSFUNCTION; BLADDER EPITHELIUM; BLOOD TOXICITY; CLINICAL TRIAL; CYSTALGIA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; ELECTRIC CURRENT; ELECTRIC RESISTANCE; ERYTHEMA; HEAT SENSITIVITY; HUMAN; HYDROGEL; HYDROPHILICITY; HYDROPHOBICITY; MACROMOLECULE; NEUROGENIC BLADDER; NEUROLOGIC DISEASE; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; REVIEW; SKIN TINGLING; SUSTAINED DRUG RELEASE; TIGHT JUNCTION; UROTHELIUM;

ABSORPTION; ADMINISTRATION, INTRAVESICAL; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; DRUG DELIVERY SYSTEMS; HUMANS; URINARY BLADDER DISEASES; UROTHELIUM;

EID: 33750610788     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.08.025     Document Type: Review

References (72)

1. Brendler T.B., Appell R.A., Lopez M.A., et al. Pharmacokinetic evaluation of intravesical oxybutynin: bolus and continuous delivery. J Urol 165 (2001) 252 (abstract no. 1039)
2. Lazzeri M., Spinelli M., Zanollo L., and Turini D. Intravesical vanilloids and neurogenic incontinence: ten years experience. Urol Int 72 (2004) 145-149
3. Giannantoni A., Di Stasi S.M., Stephen R.L., et al. Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. J Urol 167 (2002) 1710-1714
4. de Seze M., Wiart L., de Seze M.P., et al. Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a double-blind, randomized, controlled study. J Urol 171 (2004) 251-255
5. Tyagi P., Chancellor M.B., Li Z., et al. Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes. J Urol 171 (2004) 483-489
6. Parsons C.L., Lilly J.D., and Stein P. Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol 145 (1991) 732-735
7. Lewis S.A. Epithelial electrophysiology. In: Wills N.K., Reuss L., and Lewis S.A. (Eds). Epithelial transport: a guide to methods and experimental analysis (1996), Chapman & Hall, London 93-117
8. + transport by rabbit urinary bladder, a tight epithelium. J Membr Biol 28 (1976) 1-40
9. Ping H., Meyers S., Liang F., et al. Role of membrane proteins in permeability barrier function: uroplakin ablation elevates urothelial permeability. Am J Physiol Renal Physiol 283 (2002) 200-207
10. Negrete H.O., Lavelle J.P., Berg J., Lewis S.A., and Zeidel M.L. Permeability properties of the intact mammalian bladder epithelium. Am J Physiol 271 (1996) 886-894
11. Lewis S.A. Everything you wanted to know about the bladder epithelium but were afraid to ask. Am J Physiol Renal Physiol 278 (2000) 867-874
12. Hohlbrugger G., and Lentsch P. Intravesical ions, osmolality and pH influence the volume pressure response in the normal rat bladder and this is more pronounced after DMSO. Eur Urol 11 (1985) 127-130
13. Mann F.C., and Magoun J.A.H. Absorption from the urinary bladder. Am J Med Sci 166 (1923) 96-106
14. Kerec M., Bogataj M., Veranic P., and Mrhar A. Permeability of pig urinary bladder wall: the effect of chitosan and the role of calcium. Eur J Pharm Sci 25 (2005) 113-121
15. Holz R., and Finkelstein A. The water and nonelectrolyte permeability induced in thin lipid membranes by the polyene antibiotics nystatin and amphotericin B. J Gen Physiol 56 (1970) 124-145
16. Chuang Y.C., Yoshimura N., Huang C.C., Chaing P.H., and Chancellor M.B. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 172 (2004) 1529-1532
17. Vemulakonda V.M., Somogyi G.T., Kiss S., Salas N.A., Boone T.B., and Smith C.P. Inhibitory effects of intravesically applied botulinum toxin a in chronic bladder inflammation. J Urol 173 (2005) 621-624
18. Lavelle J., Meyers S., Ramage R., et al. Bladder permeability barrier: recovery from selective injury of surface epithelial cells. Am J Physiol Renal Physiol 283 (2002) 242-253
19. Cetinel S., Ercan F., Sirvanci S., et al. The ameliorating effect of melatonin on protamine sulfate induced bladder injury and its relationship to interstitial cystitis. J Urol 169 (2003) 1564-1568
20. Aydin H., Ercan F., Cetinel S., and San T. Morphological examination of the effects of defibrotide on experimentally induced bladder injury and its relation to interstitial cystitis. Urol Res 29 (2001) 263-271
21. Melchior D., Packer C.S., Johnson T.C., and Kaefer M. Dimethyl sulfoxide: does it change the functional properties of the bladder wall?. J Urol 170 (2003) 253-258
22. See W.A., and Xia Q. Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity. J Natl Cancer Inst 84 (1992) 510-515
23. Phipps J.B., Padmanabhan R.V., and Lattin G.A. Iontophoretic delivery of model inorganic and drug ions. J Pharm Sci 78 (1989) 365-369
24. Lugnani F., Mazza G., Cerulli N., Rossi C., and Stephen R.L. Iontophoresis of drugs in the bladder wall: equipment and preliminary studies. Artif Organs 17 (1993) 8-17
25. Gurpinar T., Truong L.D., Wong H.Y., and Griffith D.P. Electromotive drug administration to the urinary bladder: an animal model and preliminary results. J Urol 156 (1996) 1496-1501
26. Turnell W.J. Therapeutic action of constant current. Proc R Soc Med 14 (1921) 41-52
27. Sloan J.B., and Soltani K. Iontophoresis in dermatology. J Am Acad Dermatol 15 (1986) 617-684
28. Glass J.M., Stephen R.L., and Jacobson S.C. The quantity and distribution of radiolabeled dexamethasone delivered to tissue by iontophoresis. Int J Dermatol 19 (1980) 519-524
29. Di Stasi S.M., Giannantoni A., Vespasiani G., et al. Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens. J Urol 165 (2001) 491-498
30. Di Stasi S.M., Giannantoni A., Navarra P., et al. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin. J Urol 166 (2001) 2232-2236
31. Di Stasi S.M., Giannantoni A., Stephen R.L., et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 170 (2003) 777-782
32. Di Stasi S.M., Giannantoni A., Giurioli A., et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomized controlled trial. Lancet Oncol 7 (2006) 43-51
33. Colombo R., Brasi M., Da Pozzo L., et al. Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. A pilot study on marker lesions. Eur Urol 39 (2001) 95-100
34. Di Stasi SM, Giannantoni A, Massoud R, et al. Comparative bladder wall tissue levels of resiniferatoxin. In: Proc. Abstract Book of the ICS 34th Annual meeting, Paris, 25-27 August 2004 (abstract no. 577).
35. Di Stasi S., Giannantoni A., Massoud R., Navarra P., Vespasiani G., Porena M., and Stephen R. Stability of resiniferatoxin stock solution. Eur Urol Suppl 3 2 (2004) 106 (abstract no. 414)
36. Di Stasi S.M., Giannantoni A., Stephen R.L., et al. A prospective randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol 171 (2004) 1605-1608
37. Riedl C.R., Daha L.K., Knoll M., and Pflueger H. Betanechol in the restitution of the acontractile detrusor: a prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn 21 (2002) 376 (abstract no. 71A)
38. Di Stasi S.M., Giannantoni A., Navarra P., et al. The stability of lidocaine and epinephrine solutions exposed to electric current and comparative administrations rates of the two drugs into pig bladder wall. Urol Res 31 (2003) 169-176
39. Massoud R., Federici G., Casciani S., et al. Extraction and determination of oxybutynin in human bladder samples by reversed-phase high-performance liquid chromatography. J Chromatogr B 734 (1999) 163-167
40. Di Stasi S.M., Giannantoni A., Massoud R., Cortese C., Vespasiani G., and Micali F. Electromotive administration of oxybutynin into the human bladder wall. J Urol 158 (1997) 228-233
41. Di Stasi S.M., Vespasiani G., Giannantoni G., Massoud R., Dolci S., and Micali F. Electromotive delivery of mitomycin C into the human bladder wall. Cancer Res 57 (1997) 875-880
42. Di Stasi S.M., Giannantoni A., Massoud R., et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res 59 (1999) 4912-4918
43. Brausi M., Campo B., Pizzocaro G., et al. Intravesical electromotive administration of drugs for treatment of superficial bladder: a comparative phase II study. Urology 51 (1998) 506-509
44. Stenzl A., Eder I., Kostron H., Klocker H., and Bartsch G. Electromotive diffusion (EMD) and photodynamic therapy with delta-aminolevulinic acid (delta-ALA) for superficial bladder cancer. J Photochem Photobiol B 36 (1996) 233-236
45. Jewett M.A.S., Valiquette L., Sampson H.A., Katz J., Fradet Y., and Redelmeier D.A. Electromotive drug administration of lidocaine as an alternative anesthesia for transurethral surgery. J Urol (1999) 482-485
46. Fontanella U.A., Rossi C.A., and Stephen R.L. Bladder and urethral anaesthesia with electromotive drug administration (EMDA): a technique for invasive endoscopic procedures. Br J Urol 79 (1997) 414-420
47. Schurch B., Reitz A., and Tenti G. Electromotive drug administration of lidocaine to anesthetize the bladder before botulinum-A toxin injections into the detrusor. Spinal Cord 42 (2004) 338-341
48. Dasgupta P., Fowler C.J., Hoverd P., et al. Does electromotive drug administration (EMDA) with lignocaine before intravesical capsaicin confer benefit?. J Urol 157 (1997) 186 (abstract no. 724)
49. Riedl C., Knoll M., Plas E., Stephen R.L., and Pfluger H. Intravesical electromotive drug administration for the treatment of non-infectious chronic cystitis. Int Urogynecol J Pelvic Floor Dysfunct 8 (1997) 134-137
50. Riedl C., Knoll M., Plas E., and Pfluger H. Electromotive drug administration and hydrodistention for the treatment of interstitial cystitis. J Endourol 12 (1998) 269-272
51. Rosamilia A., Dwyer P.L., and Jbson J. Electromotive drug administration of lidocaine and dexamethasone followed by cystodistension in women with interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct 8 (1997) 142-145
52. Hinkel A., and Pannek J. Transient ischemic attack after electromotive drug administration for chronic non-infectious cystitis: report of two similar cases. Neurourol Urodyn 23 (2004) 180-182
53. Rose E.A., Azevedo K.J., and Payne C.K. Office bladder distension with electromotive drug administration (EMDA) is equivalent to distension under general anesthesia. BMC Urol 5 (2005) 14-18
54. Rose A.E., Payne C.K., and Azevedo K. Pilot study of the feasibility of in-office bladder distention using electromotive drug administration (EMDA). Neurourol Urodyn 24 (2005) 254-260
55. Sasaki M., Hashimoto H., and Yachiku S. Studies on enhancement of drug absorption through the bladder mucosa. Nippon Hinyokika Gakkai Zasshi 85 (1994) 1353-1362
56. Hashimoto H., Yachiku S., Watanabe Y., et al. Postoperative intravesical installation of tetrahydropyranyl-adriamycin (THP) and cytosine arabinoside (CA) for superficial bladder cancer: clinical results of prophylactic effects on recurrence. Gan To Kagaku Ryoho 21 (1994) 833-838
57. Schwarze S.R., Ho A., Vocero-Akbani A., and Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 (1999) 1569-1572
58. Nielsen P.E. Gene targeting using peptide nucleic acid. Methods Mol Biol 288 (2005) 343-358
59. Pooga M., Land T., Bartfai T., and Langel U. PNA oligomers as tools for specific modulation of gene expression. Biomol Eng 17 (2001) 183-192
60. Frangos D.N., Killion J.J., Fan D., et al. The development of liposomes containing interferon alpha for the intravesical therapy of human superficial bladder cancer. J Urol 143 (1990) 1252-1256
61. Lazzeri M., Spinelli M., Beneforti P., Malaguti S., Giardiello G., and Turini D. Intravesical infusion of resiniferatoxin by a temporary in situ drug delivery system to treat interstitial cystitis: a pilot study. Eur Urol 45 (2004) 98-102
62. Shurafa M., Shumaker E., and Cronin S. Prostaglandin F2-alpha bladder irrigation for control of intractable cyclophosphamide-induced hemorrhagic cystitis. J Urol 137 (1987) 1230-1231
63. Trigg M.E., O'Reilly J., Rummelhart S., Morgan D., Holida M., and de Alarcon P. Prostaglandin E1 bladder instillations to control severe hemorrhagic cystitis. J Urol 143 (1990) 92-94
64. Miller L.J., Chandler S.W., and Ippoliti C.M. Treatment of cyclophosphamide-induced hemorrhagic cystitis with prostaglandins. Ann Pharmacother 28 (1994) 590-594
65. Ronneberger B., Kao W.Y., Anderson J.M., and Kissel T. In vivo biocompatibility study of ABA triblock copolymers consisting of poly(L-lactic-co-glycolic acid) A blocks attached to central poly(oxyethylene) B blocks. J Biomed Mater Res 30 (1996) 31-40
66. Jeong B., Bae Y.H., and Kim S.W. Drug release from biodegradable injectable thermosensitive hydrogel of PEG-PLGA-PEG triblock copolymers. J Control Release 63 (2000) 155-163
67. Jeong B., Bae Y.H., and Kim S.W. In situ gelation of PEG-PLGA-PEG triblock copolymer aqueous solutions and degradation thereof. J Biomed Mat Res 50 (2000) 171-177
68. Tyagi P., Li Z., Chancellor M.B., de Groat W.C., Yoshimura N., and Huang L. Sustained intravesical drug delivery using thermosensitive hydrogel. Pharm Res 21 (2004) 832-837
69. Bangham A.D. A correlation between surface charge and coagulant action of phospholipids. Nature 192 (1961) 1197-1198
70. Johnson J.W., Nayar R., Killion J.J., von Echenbach A.C., and Fidler I.J. Bindings of liposomes to human bladder tumor epithelial cell lines: implications for an intravesical drug delivery system for the treatment of bladder cancer. Sel Cancer Ther 5 (1989) 147-155
71. Tyagi P., Chancellor M.B., Li Z., et al. Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes. J Urol 171 (2004) 483-489
72. Fraser M.O., Chuang Y.C., Tyagi P., et al. Intravesical liposome administration-a novel treatment for hyperactive bladder in the rat. Urology 3 (2003) 656-663